Cargando…

Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity

BACKGROUND: Stereotactic ablative radiotherapy (SABR) offers an alternative treatment for pancreatic cancer, with the potential for improved tumour control and reduced toxicity compared with conventional therapies. However, optimal dose planning and delivery strategies are unelucidated and gastro-in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldsmith, Christy, Plowman, P. Nicholas, Green, Melanie M., Dale, Roger G., Price, Patricia M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194644/ https://www.ncbi.nlm.nih.gov/pubmed/30340643 http://dx.doi.org/10.1186/s13014-018-1138-3

Ejemplares similares

Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
por: Goldsmith, Christy, et al.
Publicado: (2012)

Technical know‐how in stereotactic ablative radiotherapy (SABR)
por: Lo, Simon S., et al.
Publicado: (2016)

Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists
por: Li, Shan, et al.
Publicado: (2020)

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
por: Olson, Robert, et al.
Publicado: (2018)

Quantification of interplay and gradient effects for lung stereotactic ablative radiotherapy (SABR) treatments
por: Tyler, Madelaine K.
Publicado: (2016)

Stereotactic ablative radiotherapy (SABR) for recurrent and previously irradiated head and neck cancers
por: Anand, Anil Kumar, et al.
Publicado: (2020)

A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
por: Correa, Rohann J. M., et al.
Publicado: (2018)

Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR)
por: Nicolae, Alexandru, et al.
Publicado: (2015)

Optimal and actual rates of Stereotactic Ablative Body Radiotherapy (SABR) utilisation for primary lung cancer in Australia
por: Ghandourh, Wsam, et al.
Publicado: (2022)

Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results
por: Boda-Heggemann, Judit, et al.
Publicado: (2012)

Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach
por: Comito, Tiziana, et al.
Publicado: (2014)

Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours
por: Masucci, Giuseppe V, et al.
Publicado: (2012)

Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors
por: Binkley, Michael S., et al.
Publicado: (2016)

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
por: David, Steven, et al.
Publicado: (2019)

Restricted bowel loop contouring: Improving efficiency in radiotherapy contouring for abdomino-pelvic Stereotactic Ablative Radiotherapy (SABR)
por: Clarke, Eleanor, et al.
Publicado: (2020)

HIF-1α Inhibition Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR)
por: Song, Chang W., et al.
Publicado: (2022)

Volumetric modulated arc therapy (VMAT) comparison to 3D‐conformal technique in lung stereotactic ablative radiotherapy (SABR)
por: Mark, Frances, et al.
Publicado: (2022)

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
por: Palma, David A, et al.
Publicado: (2012)

Developing a class solution for Prostate Stereotactic Ablative Body Radiotherapy (SABR) using Volumetric Modulated Arc Therapy (VMAT)
por: Murray, Louise J., et al.
Publicado: (2014)

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
por: Palma, David A., et al.
Publicado: (2020)

Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma
por: Reynolds, Hayley M., et al.
Publicado: (2018)

Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR)
por: Dhaliwal, Inderdeep, et al.
Publicado: (2022)

Stereotactic ablative body radiotherapy (SABR) lung fractionations locally in the COVID-19 era and the impact on dosimetry, resources, early toxicities, and the environment
por: Phelps, Lyndsey, et al.
Publicado: (2021)

Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial
por: Chen, Liang-Cheng, et al.
Publicado: (2019)

To gate or not to gate - dosimetric evaluation comparing Gated vs. ITV-based methodologies in stereotactic ablative body radiotherapy (SABR) treatment of lung cancer
por: Kim, Joshua, et al.
Publicado: (2016)

Treatment-related neuroendocrine prostate cancer managed with partial stereotactic ablative radiotherapy (P-SABR) for long-term survival: a case series
por: Qi, Xin, et al.
Publicado: (2023)

Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma
por: Vordermark, Dirk, et al.
Publicado: (2005)

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
por: Lieverse, Relinde I. Y., et al.
Publicado: (2020)

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
por: Palma, David A., et al.
Publicado: (2019)

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
por: Olson, Robert, et al.
Publicado: (2020)

NRG-GU012: randomized phase II stereotactic ablative radiation therapy (SABR) for metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI)
por: McKay, Rana
Publicado: (2023)

Stereotactic Radiotherapy: An Alternative Option for Refractory Ventricular Tachycardia to Drug and Ablation Therapy
por: Shangguan, Wenfeng, et al.
Publicado: (2022)

Evaluation of CyberKnife® Fiducial Tracking Limitations to Assist Targeting Accuracy: A Phantom Study with Fiducial Displacement
por: Goldsmith, Christy, et al.
Publicado: (2018)

Quantification of hyperpolarisation efficiency in SABRE and SABRE-Relay enhanced NMR spectroscopy
por: Richardson, Peter M., et al.
Publicado: (2018)

Technical Note: Dosimetric evaluation of Monte Carlo algorithm in iPlan for stereotactic ablative body radiotherapy (SABR) for lung cancer patients using RTOG 0813 parameters
por: Pokhrel, Damodar, et al.
Publicado: (2015)

Stereotactic ablative body radiotherapy (SABR) for inoperable, chemorefractory retroperitoneal lymph node relapse from non seminomatous germ cell tumour of testis: a case report
por: Gulia, Abhishek, et al.
Publicado: (2018)

SABR-BRIDGE: Stereotactic ABlative Radiotherapy Before Resection to AvoId Delay for Early-Stage LunG Cancer or OligomEts During the COVID-19 Pandemic
por: Kidane, Biniam, et al.
Publicado: (2020)

Systematic review of economic evaluations on stereotactic ablative radiotherapy (SABR) compared to other radiotherapy techniques or surgical procedures for early-stage non-small cell lung cancer
por: Maia, Fernando Henrique de Albuquerque, et al.
Publicado: (2023)

Study protocol for prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC)
por: Kim, Yong Bae, et al.
Publicado: (2023)

Strategies for the Hyperpolarization of Acetonitrile and Related Ligands by SABRE
por: Mewis, Ryan E., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5778o3bjc65sumb3v5qqng0s7v